Moderna’s (MRNA) “Market Perform” Rating Reiterated at William Blair

by · The Cerbat Gem

William Blair reiterated their market perform rating on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report sent to investors on Monday,RTT News reports.

Several other research analysts have also recently issued reports on MRNA. Morgan Stanley lowered their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. UBS Group cut their price target on shares of Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Evercore ISI decreased their price objective on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Citigroup started coverage on Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective on the stock. Finally, Royal Bank of Canada cut their target price on Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $53.58.

Get Our Latest Stock Report on MRNA

Moderna Price Performance

Shares of NASDAQ MRNA opened at $27.27 on Monday. The business has a 50-day moving average of $26.23 and a two-hundred day moving average of $33.71. The company has a market capitalization of $10.55 billion, a price-to-earnings ratio of -2.94 and a beta of 1.86. Moderna has a 1 year low of $23.15 and a 1 year high of $158.82.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business’s quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter last year, the company earned ($3.07) EPS. As a group, equities research analysts expect that Moderna will post -9.61 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. S Bank Fund Management Ltd acquired a new position in Moderna in the 1st quarter valued at $25,000. SVB Wealth LLC acquired a new stake in shares of Moderna in the 1st quarter worth $28,000. Costello Asset Management INC acquired a new stake in shares of Moderna in the 1st quarter worth $30,000. Sentry Investment Management LLC purchased a new stake in shares of Moderna in the first quarter valued at about $31,000. Finally, Deseret Mutual Benefit Administrators increased its stake in shares of Moderna by 53.3% during the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after acquiring an additional 392 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also